**Supplemental Table 8** Proportion of Visual Changes and Persistent Macular Thickening During the Study Period for Eyes Treated with Intravitreal Bevacizumab Monotherapy (Complete Case Analysis)

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Month 12****% (95% CI)** | **Month 24****% (95% CI)** | **Month 36****% (95% CI)** |
| Proportion of eyes gaining ≥10 letters  | 43.1(36.8 to 49.4) | 38.9(31.6 to 46.2) | 36.2 (26.7 to 45.7) |
| Proportion of eyes gaining ≥15 letters | 35.5 (29.7 to 41.3) | 31.2 (24.6 to 37.8) | 30.5(21.7 to 39.3) |
| Proportion of eyes losing ≥10 letters | 12.1 (7.8 to 16.4) | 18.3 (12.6 to 23.9) | 20.0 (12.7 to 27.3) |
| Proportion of eyes losing ≥15 letters | 8.9 (5.1 to 12.5) | 13.7 (8.6 to 18.8) | 17.4(11.7 to 24.9) |
| Proportion of eyes with CSFT ≥ gender specific criteria (female ≥ 305, male ≥ 320 µm) | 65.0 (57.9 to 72.1) | 51.1 (42.1 to 60.1) | 50.2 (39.5 to 60.9) |
| *CSFT = central subfield thickness, CI = confidence interval* |